TLX

Telix Pharmaceuticals Limited American Depositary Shares

17.40 USD
+0.04
0.23%
At close Apr 30, 4:00 PM EDT
1 day
0.23%
5 days
-5.84%
1 month
3.82%
3 months
-4.40%
6 months
14.85%
Year to date
16.00%
1 year
14.85%
5 years
14.85%
10 years
14.85%
 

About: Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Employees: 554

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

0% more ownership

Funds ownership: 0% [Q3] → 0% (+0%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for TLX.

Financial journalist opinion

Based on 14 articles about TLX published over the past 30 days

Neutral
Accesswire
15 hours ago
TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited
Neutral
GlobeNewsWire
2 days ago
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
Neutral
Accesswire
2 days ago
Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / April 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud
Neutral
GlobeNewsWire
1 week ago
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Telix Pharmaceuticals reported strong Q1 2025 revenue of $186 million, up 62% year-on-year, driven by Illuccix® sales and RLS Radiopharmacies acquisition.
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Positive
Benzinga
2 weeks ago
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Telix Pharmaceuticals Limited   TLX on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study.
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Neutral
GlobeNewsWire
2 weeks ago
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study2.
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Positive
Zacks Investment Research
2 weeks ago
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Positive
Zacks Investment Research
3 weeks ago
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Telix Shares May Gain on the Distribution Deal With Cardinal Health
Neutral
GlobeNewsWire
3 weeks ago
Telix Announces Cardinal Health for Gozellix Commercial Distribution
MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer in the United States (U.S.).
Telix Announces Cardinal Health for Gozellix Commercial Distribution
Neutral
GlobeNewsWire
3 weeks ago
Telix Appoints Paul Schaffer as Chief Technology Officer
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.
Telix Appoints Paul Schaffer as Chief Technology Officer
Charts implemented using Lightweight Charts™